23 May 2024
The Ministry of Health of the Russian Federation has recently approved a new drug for the treatment of ankylosing spondylitis, which is now in production and is expected to be available for sale in approximately three months. However, its testing is still ongoing, said Russian Health Minister Mikhail Murashko.
In Russia there are about 250 thousand patients with ankylosing spondylitis. This is a chronic disease in which antibodies mistake the cartilage tissue and joints of the body as foreign. Causes pain and stiffness in the spine, potentially leading to limited mobility.
According to the Russian Ministry of Health, the newly developed drug enables the destruction of pathological T-lymphocytes which harm the body’s own cells.
PrintNovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
16 May 2024
06 September 2024
HPV vaccine is to be included in Russia’s national immunization schedule by 2026
06 September 2024
New WHO guidance to support manufacturers to reduce AMR risk
05 September 2024
05 September 2024